Hai T. Tran, Pharm D
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
About Dr. Tran
After receiving my bachelor degree in pharmacy in 1998 from Temple University, I completed a pharmacy residency training program and worked as a clinical pharmacist for 2 years at the Medical Center of Delaware. In 1994, I received my doctor of pharmacy degree from University of Kentucky. Then I went to complete a hematology/oncology pharmacy residency and clinical pharmacology fellowship at the University of Texas MD Anderson Cancer Center. Since completing my fellowship in August 1997, one of my research efforts had been the implementation of a dose individualization program with the adult and pediatric stem cell transplant programs here at MD Anderson Cancer Center with our Stem Cell Transplant (SCT) group in the use of high-dose busulfan in many SCT preparative regimen.. I led the development of the cancer center’s phase I/II research unit and was the director of the Clinical and Translation Research Center from 1997 until 2001 which I took from 1 room to a 10-room unit. Another area in which I have a particular interest is evaluation of interactions between two or more medications in individual patients. In an attempt to better define and understand these interactions between varieties of chemotherapeutic agents, preclinical experiments are done in both in-vitro and in-vivo models. Especially with novel molecular targeting agents, these sequence-specific experiments are designed to take advantage of the mechanism of activity of the individual agent. Once these mechanistic and results are validated, a potential is to bring these compound(s) into the clinic. Over the last several years, I have been collaborating with many of our faculty to develop and validate potential blood-based biomarker(s) of lung and head & neck cancers. This work has led us to identify several potential groups of blood-based markers correlating with therapeutic response or resistance. Additionally, current research has also focused on isolation and identification of molecular alterations from these rare circulating tumor cells and tumor DNA. As a part of our team lung cancer moon shot effort, I am leading the cell line drug screening; i.e., "re-purposing" old drugs for potentially new treatment for our patients with lung cancer.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1994 | University of Kentucky, College of Pharmacy, Lexington, KY, USA, PHARMD, Doctor of Pharmacy |
| 1989 | Temple University, School of Pharmacy, Philadelphia, PA, USA, B.S. Pharmacy, Pharmacy |
| 1986 | University of Dayton, Dayton, OH, USA, Pre-Pharmacy, Pharmacy |
Selected Publications
Peer-Reviewed Articles
- Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9(415), 2017. PMID: 29118262.
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran HT, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-90, 2013. e-Pub 2012. PMID: 23091115.
- Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827-37, 2012. e-Pub 2012. PMID: 22759480.
- Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 2012. e-Pub 2011. PMID: 22006179.
- Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. J Thorac Oncol 6(12):2104-11, 2011. e-Pub 2011. PMID: 21892101.
- Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 4(10):1590-8, 2011. e-Pub 2011. PMID: 21764858.
- De Groot JF, Piao Y, Tran HT, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17(14):4872-81, 2011. e-Pub 2011. PMID: 21632852.
- Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 2011. e-Pub 2010. PMID: 20094773.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein Jr GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 1(1):44-53, 2011. e-Pub 2011.
- Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 2011. e-Pub 2010. PMID: 21523723.
- Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat(r) classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3):337-340, 2010. PMID: 20036440.
- Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S, Fiorentino S, Milas ZL, Kosynkin DV, Price BK, Lucente-Schultz RM, Wen X, Raso MG, Craig SL, Tran HT, Myers JN, Tour JM. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 4(8):4621-36, 2010. PMID: 20681596.
- Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 2010. e-Pub 2010. PMID: 20530716.
- Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70(6):2171-9, 2010. e-Pub 2010. PMID: 20215520.
- Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients with Non-Small-Cell Lung Cancer. J Clin Oncol 28(2):193-201, 2010. e-Pub 2009. PMID: 19949019.
- Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated with Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2009. PMID: 20008624.
- Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in Patients with Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol 32(3):274-279, 2009. PMID: 19433965.
- Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands Jagged-1 and Jagges-2. J Biol Chem 284(26):17766-74, 2009. e-Pub 2009. PMID: 19398556.
- Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran HT, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97(22):1695-9, 2005. PMID: 16288123.
- Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892-9, 2005. PMID: 16043829.
- Abramson DH, Frank CM, Chantada GL, de Totah AB, de Pifano IT, Ramirez GT, Gomez RT, Fandino AT, Tran HT, Madden TJ, Dunkel IJ. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet 20(1):31-6, 1999. PMID: 10415463.
- Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116(9):1209-12, 1998. PMID: 9747681.
- Worth LL, Tran HT, Madden T, Przepiorka D, Chan KW, Jaffe N. High-dose busulfan, thiotepa, and cyclophosphamide: an effective preparative regimen for stem cell transplantation for myeloid malignancies in children. Journal of Pediatric Hematology/Oncology 20(4):375, 1998.
- Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-802, 1997. PMID: 9164187.
Book Chapters
- Tran HT, Tett T. Therapeutic drug monitoring in hematopoietic stem cell transplant recipients. In: Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd. Cambridge Press: Cambridge, England, 505-514, 2004.
Grant & Contract Support
| Title: | Evaluation of Circulating Plasma Biomarkers in Subjects Enrolled in the Exelixis XL 184-202 Clinical Trial |
| Funding Source: | Exelixis Inc |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 13, 2024